The therapeutic implications of this interaction relate to enhancing and promoting Aβ clearance mechanisms in AD, reducing or preventing Aβ aggregation and toxicity, as well as potentially identifying peptide mimics of the apoA-I interacting region with Aβ [75]. The gene discussed is APOA1; the disease is Alzheimer disease.